Latest Period
Q1 2026
Security Snapshot
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) Institutional Ownership
CUSIP: H0036K147
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
118
Shares (Excl. Options)
83,513,765
Price
$3.75
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Symbol
- ADCT on NYSE
- Shares outstanding
- 128,459,465
- Price per share
- $3.76
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 83,513,765
- Total reported value
- $312,902,534
- % of total 13F portfolios
- 0%
- Share change
- +1,276,593
- Value change
- +$4,946,064
- Number of holders
- 118
- Price from insider filings
- $3.76
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share is tracked under CUSIP H0036K147.
- 118 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 115 to 118 between Q4 2025 and Q1 2026.
- Reported value moved from $292,847,655 to $312,902,534.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 118 institutions filings for Q1 2026.
Security key
H0036K147
Latest holder period
Q1 2026
13F holders
118
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
ADCT full holder history
ADC Therapeutics SA SEC filings
ADC Therapeutics SA company facts
ADC Therapeutics SA insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H0036K147:
Significant Owners of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | 0% | $47,690,576 | +$92,422 | 12,717,487 | +0.19% | Redmile Group, LLC | 20 Apr 2026 |
| TCG Crossover GP II, LLC | 9.2% | $42,143,648 | 11,390,175 | TCG Crossover GP II, LLC | 27 Oct 2025 | |||
| HPWH TH AG | 9.6% | $14,291,858 | 9,788,944 | Dr. Hans-Peter Wild | 15 May 2025 | |||
| Prosight Management, LP | 6.8% | +17% | $31,366,151 | +$4,743,267 | 8,477,338 | +18% | Prosight Management, LP | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4% | -43% | $18,554,083 | -$10,422,190 | 5,014,617 | -36% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| BlackRock, Inc. | 5% | -4% | $7,173,203 | -$144,108 | 4,913,153 | -2% | BlackRock, Inc. | 31 Mar 2025 |
| Oaktree Capital Group Holdings GP, LLC | 4.1% | $18,693,764 | 4,673,441 | Oaktree Fund Administration, LLC | 30 Sep 2025 | |||
| ORBIMED ADVISORS LLC | 2.6% | -25% | $11,953,949 | -$765,959 | 3,230,797 | -6% | ORBIMED CAPITAL LLC | 31 Dec 2025 |
As of 31 Mar 2026, 118 institutional investors reported holding 83,513,765 shares of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT). This represents 65% of the company’s total 128,459,465 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12% | 15,470,502 | -1.3% | 3.8% | $58,014,383 |
| TCG Crossover Management, LLC | 8.9% | 11,390,175 | 0% | 1.2% | $42,713,156 |
| Prosight Management, LP | 6.5% | 8,300,000 | -2.1% | 5.1% | $31,125,000 |
| BlackRock, Inc. | 4.9% | 6,250,747 | +15% | 0% | $23,440,301 |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.4% | 5,701,655 | +69% | 0.35% | $21,381,206 |
| Nantahala Capital Management, LLC | 4.4% | 5,597,433 | +2.2% | 1.3% | $20,990,374 |
| MORGAN STANLEY | 3% | 3,812,582 | +1.1% | 0% | $14,297,184 |
| Point72 Asset Management, L.P. | 2.6% | 3,382,129 | -33% | 0.02% | $12,682,984 |
| MILLENNIUM MANAGEMENT LLC | 2.4% | 3,119,154 | +850% | 0.01% | $11,696,828 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,653,026 | +0.74% | 0% | $6,198,848 |
| STATE STREET CORP | 1.2% | 1,566,662 | +11% | 0% | $5,874,983 |
| BANK OF AMERICA CORP /DE/ | 1% | 1,325,017 | +2% | 0% | $4,968,813 |
| ORBIMED ADVISORS LLC | 1% | 1,318,026 | -77% | 0.11% | $4,942,598 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.94% | 1,203,756 | +21% | 0% | $4,514,085 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.8% | 1,033,277 | 0% | 0% | $3,874,789 |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0.77% | 990,778 | 0% | 0.94% | $3,715,418 |
| BNP PARIBAS FINANCIAL MARKETS | 0.67% | 860,491 | 0% | 0% | $3,226,841 |
| Blue Owl Capital Holdings LP | 0.57% | 733,568 | 0% | 0.7% | $2,589,495 |
| PANAGORA ASSET MANAGEMENT INC | 0.54% | 691,275 | +16% | 0.01% | $2,592,281 |
| TWO SIGMA INVESTMENTS, LP | 0.52% | 668,022 | +459% | 0% | $2,505,083 |
| NORTHERN TRUST CORP | 0.43% | 552,201 | +26% | 0% | $2,070,754 |
| Voleon Capital Management LP | 0.4% | 513,831 | +11% | 0.04% | $1,926,866 |
| JPMORGAN CHASE & CO | 0.38% | 489,079 | +3.7% | 0% | $1,780,248 |
| UBS Group AG | 0.36% | 458,902 | +113% | 0% | $1,720,883 |
| ACADIAN ASSET MANAGEMENT LLC | 0.35% | 449,122 | -15% | 0% | $1,680,000 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 83,513,765 | $312,902,534 | +$4,946,064 | $3.75 | 118 |
| 2025 Q4 | 82,866,392 | $292,847,655 | +$51,266,809 | $3.53 | 115 |
| 2025 Q3 | 68,158,412 | $272,625,712 | -$9,526,921 | $4.00 | 105 |
| 2025 Q2 | 67,952,003 | $182,114,158 | +$35,606,077 | $2.68 | 84 |
| 2025 Q1 | 54,846,167 | $77,332,587 | -$2,528,133 | $1.41 | 82 |
| 2024 Q4 | 56,494,277 | $112,422,732 | -$3,041,138 | $1.99 | 82 |
| 2024 Q3 | 54,883,537 | $172,881,709 | +$3,394,419 | $3.15 | 76 |
| 2024 Q2 | 51,801,951 | $163,693,841 | +$51,364,315 | $3.16 | 73 |
| 2024 Q1 | 34,683,534 | $155,728,721 | +$7,168,355 | $4.49 | 36 |
| 2023 Q4 | 33,953,461 | $56,361,695 | -$3,915,509 | $1.66 | 36 |
| 2023 Q3 | 39,458,503 | $35,390,528 | -$10,272,333 | $0.90 | 40 |
| 2023 Q2 | 45,357,348 | $97,515,460 | -$1,939,928 | $2.15 | 55 |
| 2023 Q1 | 46,611,135 | $90,890,151 | +$6,156,453 | $1.95 | 57 |
| 2022 Q4 | 38,834,584 | $149,117,927 | +$3,712,534 | $3.84 | 59 |
| 2022 Q3 | 36,621,247 | $176,523,672 | +$9,038,590 | $4.82 | 60 |
| 2022 Q2 | 34,475,113 | $274,062,429 | +$4,571,679 | $7.95 | 52 |
| 2022 Q1 | 34,123,674 | $501,279,862 | +$2,970,760 | $14.69 | 44 |
| 2021 Q4 | 33,799,357 | $682,750,000 | +$19,180,842 | $20.20 | 50 |
| 2021 Q3 | 32,792,604 | $890,647,136 | -$45,594,727 | $27.16 | 51 |
| 2021 Q2 | 33,533,099 | $816,251,800 | +$17,173,667 | $24.35 | 53 |
| 2021 Q1 | 32,826,058 | $801,283,858 | +$19,636,706 | $24.41 | 55 |
| 2020 Q4 | 32,141,073 | $1,028,835,000 | +$31,200,598 | $32.01 | 51 |
| 2020 Q3 | 28,226,306 | $921,776,783 | +$216,837,760 | $32.99 | 51 |
| 2020 Q2 | 21,557,623 | $1,000,339,109 | +$1,000,339,111 | $46.81 | 41 |